$20m · Series B · Software · Cambridge, UK
Image: Qureight.
Cambridge-based Qureight, an imaging contract research organisation for lung and heart clinical trials, has raised $20m in Series B financing led by Molten Ventures. Existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension also participated. Qureight says the capital will expand its quantitative-imaging platform, build a dedicated AI imaging laboratory and grow its commercial team.
Imaging CROs are becoming data infrastructure
Clinical-trial imaging is more than interpreting a scan. Sponsors need sites to submit images consistently, patient information to be removed, scans to pass quality checks and measurements to remain comparable across locations and timepoints. Qureight combines those operational services with AI biomarkers designed to quantify structural changes inside the lung, turning raw CT data into endpoints that drug developers can use to assess disease progression and treatment response.
The company has put that model into active development programmes. Calluna Pharma selected Qureight's 3D imaging platform for a 150-patient Phase 2 idiopathic pulmonary fibrosis study across more than 50 sites, where the software measures local changes in lung fibrosis. In a separate project with Insilico Medicine, Qureight analysed Phase IIa imaging and clinical data for rentosertib and compared the enrolled patients with its broader IPF datasets. These are company-reported collaborations, but they show the product sitting inside trial execution rather than operating as a standalone research tool.
That position matters commercially because imaging CRO work creates the workflow in which the analytics are used. A sponsor buying site onboarding, image handling and central reads can also use Qureight's quantitative biomarkers and data-science products through the same platform. If the company can make those components repeatable across studies, it can reduce handoffs for customers while accumulating experience with the data quality, regulatory controls and disease-specific endpoints required in clinical development.
A foundation model still needs disease-level proof
The new laboratory will house Qureight's 3D chest-imaging foundation model. The company says this should reduce the data and time required to develop models for additional conditions, initially asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity. That could extend one technical base across more therapeutic programmes instead of rebuilding the analysis stack for each disease.
The execution test is whether speed at the model-development stage carries through to validated trial endpoints. Each disease has different anatomy, progression patterns and clinical questions, while sponsors need outputs that remain reliable across scanners, sites and patient populations. Qureight says its management system is certified to ISO 13485 and ISO 27001 and that its platform is GxP and 21 CFR Part 11 compliant. The Series B therefore funds both expansion and a proof point: whether the company's lung-fibrosis experience can become a broader, dependable imaging layer for drug development.
Explore this theme
TechBio x AI Drug Discovery: From Concept to Reality — Speedinvest & Estelle Botbol, hosted on EUVC · 4 December 2025. Its clinical-trial-tech section explains why tools that reduce cost, time and operational risk are becoming core drug-development infrastructure.
